Patient Safety Authority Analysis Reveals High Number of Dosing Errors with Insulin Products

 

Harrisburg, PA, March 1, 2010 — Analysis of data related to insulin medication errors and a local hospital’s success in reducing hospital readmission costs are highlighted in quarterly journal.

Pennsylvania healthcare facilities submitted over 2,600 event reports that involved the use of insulin products to the Patient Safety Authority where more than 52 percent led to situations in which a patient may have or actually received the wrong dose or no dose of insulin. The data raises awareness of a broader issue that is highlighted in the 2010 March Pennsylvania Patient Safety Advisory.

Of the 2,685 event reports submitted to the Pennsylvania Patient Safety Authority between January 2008 and June 2009, 78 percent (2,113) reached the patient and in 1.8 percent of the reports (49) the patient was harmed. The most common types of medication error associated with insulin were drug omission (24.7%) followed by wrong-drug errors (13.9%).

Matthew Grissinger, RPh, FISMP, FASCP, analyst for the Pennsylvania Patient Safety Authority and director of Error Reporting Programs at the Institute for Safe Medication Practices (ISMP), said the data submitted by Pennsylvania’s healthcare facilities reflects nationwide studies. The issue not only raises concerns for the estimated 23.6 million Americans (nearly 8% of the U.S. population) who are diabetic, but also non-diabetic patients who may require insulin while in the hospital.

“The bottom line is that the better a patient’s blood glucose levels are controlled, the better quality of life that patient will lead,” Grissinger said. “It’s in the best interest of the patient for healthcare facilities to implement strategies that will help reduce the risk of medication errors associated with insulin.”

Grissinger added that in 2004 the Authority established that 25 percent of all medication errors reported involved high-alert medications of which 16.3 percent involved insulin products. Subsequently, a national study done by U.S. Pharmacopeia in 2008 shows that insulin is the leading product involved in harmful medication errors.

“Unfortunately, the issue with medication errors and insulin drugs is not new, but the Authority does offer healthcare facilities a new patient safety tool and strategies for facilities to use to help reduce the risk,” Grissinger added.

The patient safety tool allows healthcare institutions to document facility-specific process and outcome measures involving the use of insulin for better tracking of insulin-related drug events.

“In order to more successfully monitor medication safety with the use of insulin, facilities should consider other measures in addition to error reporting,” Grissinger said. “For example, the process and outcome measures we have incorporated into the tool can be utilized to determine the existence and extent of a problem as well as evaluate the effectiveness of efforts to improve the problem.”

Along with the patient safety tool, the Authority also provides patients and families with consumer tips to help them protect themselves from medication errors related to insulin products.

For more information on the data and studies related to medication errors and insulin products go to the Advisory article, “Medication Errors with Dosing of Insulin: Problems across the Continuum,” at www.patientsafetyauthority.org.